Navigation Links
La Jolla Institute identifies molecular switch enabling immune cells to better fight disease
Date:1/20/2013

ortant step to learning how to manipulate them in disease," he said, noting it could lead to novel approaches "either to turn these cells off in autoimmune disease or turn them on in infectious diseases."

He added that the finding could also have important implications in cancer. "We need all of the cytolytic machinery that we can get to try to destroy cancers," he said. "If we can learn to turn them on, I think it's reasonable to believe that these cytolytic T cells can play an important role in controlling cancer."

The findings were published today in Nature Immunology in a paper entitled "Transcriptional reprogramming of mature CD4 helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes." Dr. Cheroutre is co-senior author on the study together with Dr. Ichiro Taniuchi of the RIKEN Research Center for Allergy and Immunology in Yokohama, Kanagawa, Japan. First authors on the paper are: Mohammad Mushtaq Husain, Ph.D., of the La Jolla Institute; Daniel Mucida, Ph.D., formerly of the La Jolla Institute, now at Rockefeller University; Femke van Wijk, Ph.D., formerly of the La Jolla Institute, now at the University Medical Center Utrecht, The Netherlands, and Sawako Muroi, of the RIKEN Institute.

Mitchell Kronenberg, Ph.D., La Jolla Institute president & chief scientific officer, said the study reflects the very successful collaboration between the La Jolla Institute and RIKEN in Japan, which have joined efforts on a number of projects over the years.

In the study, the researchers found that a certain transcription factor, which are molecules in the cell nucleus that control the activity of cells, continually suppresses the killer T cell lineage in helper T cells. Using mice, the team showed that turning off this transcription factor (ThPOK) enabled the helper cells in the body's peripheral areas, like the blood, spleen and the intestine, to override their original programming and to become killer
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. La Jolla Institute discovery could lead to new way to screen drugs for adverse reactions
2. La Jolla Institute scientist discovers key step in immune system-fueled inflammation
3. La Jolla institute identifies critical cell in fighting E. coli infection
4. Diabetes Research Institute develops oxygen-generating biomaterial
5. Space research institute honors Sen. Hutchison with Pioneer Award
6. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
7. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
8. Cary Institute Hydrofracking Forum
9. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
10. Scripps Research Institute scientists develop antidote for cocaine overdose
11. NJIT, Chinas Bengbu Glass Institute sign agreement for R&D, training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Menopause Society (NAMS) has published its key, evidence-based ... everything from hot flashes to heart disease. The ... for Clinical Care of Midlife Women," was published ... . This is the first, comprehensive set of ... freely available to all clinicians who care for ...
(Date:9/16/2014)... Two Johns Hopkins neuroscientists have discovered the "molecular brakes" ... inner ear cochleas of mice. These "hair cells" translate ... the brain and are interpreted as sounds. If the ... , A summary of the research will be ... Sept. 16. , "The proteins Hey1 and Hey2 act ...
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... world,s top biodiversity hotspot for reptiles and amphibians, according ... from the University of California, Berkeley, Southern Illinois University ... The park, which encompasses lowland Amazonian rain forest, high-altitude ... well known for its huge variety of bird life, ...
... to climate change are being compiled by research groups ... various sources results in different climate projections; hence, the ... arrive at a consensus regarding future climate estimates. ... SIAM Journal on Uncertainty Quantification , authors Matthew ...
... , New Rochelle, NY, February 19, 2014Joseph C. Glorioso, ... devoted much of his research career to developing herpes ... cells. In recognition of his leadership and accomplishments, ... Gene Therapy , a peer-reviewed journal from Mary Ann ...
Cached Biology News:Peru's Manu National Park sets new biodiversity record 2Peru's Manu National Park sets new biodiversity record 3Statistics research could build consensus around climate predictions 2Statistics research could build consensus around climate predictions 3Statistics research could build consensus around climate predictions 4Joseph Glorioso, Ph.D., receives Pioneer Award 2
(Date:9/17/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... of its Common Stock and Series A Convertible Preferred ... Series A Convertible Preferred Stock is non-voting and convertible ... will be prohibited if, as a result, the holder ... of the Common Stock then outstanding. As part of ...
(Date:9/17/2014)... 17, 2014 A biodegradable polymer ... such as bacteria, fungi, and algae into smaller ... biomass, inorganic compounds, carbon dioxide, and humus in ... base and improved costs, biodegradable polymers are proving ... alternative to conventional polymers. Primary factors that are ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... Mass. , Sept. 17, 2014 ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced that it has been ... and Trademark Office on its unique delivery system ... ) to phagocytic cells for the treatment of ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... 15, 2011 Generex Biotechnology Corporation ( www.generex.com ... the status of the previously announced spinout of ... ). The Company is in the ... several transaction opportunities, including both shell companies and ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... provide an overview of the company,s business strategy at ... the UBS 2011 Global Life Sciences Conference which will ... addition, Geoffrey Nichol, M.B., Ch.B., Sangamo,s executive vice president ...
... Aperion Biologics, Inc. announced that it has reached ... Company,s clinical trial of its Z-Lig™ Anterior Cruciate Ligament ... of the knee. The randomized multicenter study commenced in ... provide safety and performance data in the reconstruction of ...
Cached Biology Technology:Generex Provides Update on Spinout of Antigen Express 2Generex Provides Update on Spinout of Antigen Express 3Generex Provides Update on Spinout of Antigen Express 4Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference 2Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial 2